Eurobio Oncology
EndoPredict: Case studies
Watch Prof. Untch’s Case Study
- 43 years old, premenopausal, pT1c, N0, G2, L0, V0, R0, ER 100%, HER2-, PR 100%, Ki67 15%, early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result supported a confident treatment decision
- Clinical validation of the test in this patient group
Get Clear Results
0 %
Risk of distant recurrence within 10 years
0 %
Absolute individualized chemotherapy benefit
0 %
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
For this case, you could say:
- Your EndoPredict result indicates that your cancer is unlikely to come back in other parts of your body.
- This result takes into account both your tumor’s gene activity and clinical information, giving a personalized view of your situation.
- It suggests there is a 92% probability that your cancer will not return within the next 10 years.
- Chemotherapy could slightly improve this probability by about 2%, but for many patients, the small benefit may not justify the potential side effects.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Based on her clear EndoPredict result, the patient and her clinician decided to proceed without chemotherapy – avoiding unnecessary side effects while feeling confident in her favorable long-term outlook.
References
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
- Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
- Vázquez-Juarez D. et al.: Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Watch Prof. Untch’s Case Study
- 50 years old, postmenopausal, pT2, N1, G2, L0, V0, R0, ER 30/80%, PR 100/90%, Ki67 10%, lobular early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result changed the treatment decision
- Clinical validation of the test in this patient group
Get Clear Results
Based on her individualized risk score. See her full report
0 %
Risk of distant recurrence within 10 years
0 %
Absolute individualized chemotherapy benefit
0 %
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
- Your EndoPredict result shows that your cancer is at low-risk of coming back in other parts of your body.
- The result combines information from your tumor’s gene activity and clinical factors to give a clear picture of your situation.
- Based on this, there is a 91% chance your cancer will not return within 10 years.
- Adding chemotherapy could increase this chance by 3%, but the small potential benefit may not outweigh the possible side effects.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test.1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Guided by her result, the patient and her clinician chose to continue treatment without chemotherapy, sparing her from potential side effects and giving them confidence in her treatment plan.
References
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
- Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
- Vázquez-Juarez D. et al.: Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Watch Prof. Untch’s Case Study
- 68 years old, pT1b (9 mm), N0, G2, L0, V0, PN0, R0, ER 100%, PR 15%, Ki67 40% early-stage breast cancer patient
- Poll of other clinicians’ case opinions
- How her EndoPredict result changed the treatment decision
- Clinical validation of the test in this patient group
Get Clear results
0 %
Risk of distant recurrence within 10 years
0 %
Absolute individualized chemotherapy benefit
0 %
5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone
Have Informed Conversations
EndoPredict results are simple to understand and straightforward to explain.
For this case, you could say:
- Your EndoPredict result shows a high-risk score.
- This means that, based on your tumor’s genes and other clinical factors, there is a 19% chance your cancer could come back within 10 years - about 1 in 5 patients.
- Chemotherapy can reduce this risk by around 8%, bringing it down to roughly 1 in 13, which may help improve your long-term outlook.
Make Confident Decisions Knowing Her Result
- Comes from the most advanced, second-generation prognostic and predictive test.1,2
- Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
- Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
- Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
- Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11
What it Meant for this Patient
Based on her clear result, this patient and her clinician decided to add adjuvant chemotherapy to her treatment plan. They could make this choice with confidence knowing that although chemotherapy might be difficult, it will significantly lower her risk of recurrence.
References
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
- Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
- Vázquez-Juarez D. et al.: Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
